Login Register Cart 0
Recent Advances in Anti-Infective Drug Discovery

Recent Advances in Anti-Infective Drug Discovery

Editor-in-Chief

ISSN (Print): 2772-4344
ISSN (Online): 2772-4352

Back
Journal Home About Journal Editorial Board Current Issue Volumes/Issues
Subscribe
Review Article

A New Era of Therapeutics: Innovation in the Treatment of Rheumatoid Arthritis

Author(s): Romi, Devkant Sharma, Anjali Sharma*orcid of author and Parul Gupta

Volume 21, Issue 1, 2026

Published on: 01 September, 2025

Page: [27 - 43] Pages: 17

DOI: 10.2174/0127724344382299250818070846

Price: $65

Become a Editorial Board Member
Become a Reviewer
Become a Editor
Become a Section Editor

Abstract

Rheumatoid arthritis is a chronic autoimmune disease with joint destruction and chronic inflammation symptoms. Conventional therapy focuses on the prevention of the progression of the disease and management of symptoms, rather than curing the disease. Emerging therapies have been developed to cure the disease, which combines conventional therapies with a novel drug delivery system. Novel therapies have better bioavailability, which is marked by reduced adverse reactions. In the following article, some of the emerging therapies focused on the notable advancement in the procurement of the RA include microRNA alteration, helper T-cell inhibition, drug repurposing, targeting sites for interleukins, and blocking of signaling pathways. Beyond pharmacological intervention, emerging therapies explore the modulation of the microbiome, epigenetic regulation, and the manipulation of immune tolerance mechanisms. These therapies offer hope for better disease control and potential advantages for future betterment.

Keywords: Rheumatoid arthritis, conventional therapy, interleukin, TNF-inhibitor, JAK-STAT inhibitor, chronic autoimmune disease.

Erratum In:
A New Era of Therapeutics: Innovation in the Treatment of Rheumatoid Arthritis

« Previous Next »

Graphical Abstract

Graphical abstract illustrating key findings of the study

[1]
Sharif K, Sharif A, Jumah F, Oskouian R, Tubbs RS. Rheumatoid arthritis in review: Clinical, anatomical, cellular and molecular points of view. Clin Anat 2018; 31(2): 216-23.
[http://dx.doi.org/10.1002/ca.22980] [PMID: 28833647]
[2]
Gascoigne F. Immunity, inflammation and infection. In: Peate I, Wild K, Nair M, Eds. Nursing Practice: Knowledge and Care. Chichester: John Wiley & Sons; 2014; pp. 464-74.
[3]
Giraud C, Lambert C, Dutheil F, Pereira B, Soubrier M, Tournadre A. The relationship between weight status and metabolic syndrome in patients with rheumatoid arthritis and spondyloarthritis. Joint Bone Spine 2021; 88(1): 105059.
[4]
Nandgude TD, Hasabe PS, Kolsure AK. Clinical features and treatment of Rheumatoid arthritis: A review. Res J Pharm Technol 2018; 11(12): 5701-6.
[http://dx.doi.org/10.5958/0974-360X.2018.01032.6]
[5]
Conforti A, Di Cola I, Pavlych V, et al. Beyond the joints, the extra-articular manifestations in Rheumatoid arthritis. Autoimmun Rev 2021; 20(2): 102735.
[http://dx.doi.org/10.1016/j.autrev.2020.102735] [PMID: 33346115]
[6]
McInnes IB, Schett G. The pathogenesis of Rheumatoid arthritis. N Engl J Med 2011; 365(23): 2205-19.
[http://dx.doi.org/10.1056/NEJMra1004965] [PMID: 22150039]
[7]
Smolen JS, Aletaha D, McInnes IB. Rheumatoid arthritis. Lancet 2016; 388(10055): 2023-38.
[http://dx.doi.org/10.1016/S0140-6736(16)30173-8] [PMID: 27156434]
[8]
Kahlon MS, Moidul Islam M, Vashishat A, Raikwar S. Revolutionizing Rheumatoid arthritis care: AI-infused herbal treatments and the road ahead. Curr Pharm Biotechnol 2025; 26(3): 316-8.
[http://dx.doi.org/10.2174/0113892010305528240506114408] [PMID: 38757330]
[9]
Feldmann M, Maini SRN. Role of cytokines in Rheumatoid arthritis: An education in pathophysiology and therapeutics. Immunol Rev 2008; 223(1): 7-19.
[http://dx.doi.org/10.1111/j.1600-065X.2008.00626.x] [PMID: 18613827]
[10]
Epstein FH, Harris ED. Rheumatoid arthritis. N Engl J Med 1990; 322(18): 1277-89.
[http://dx.doi.org/10.1056/NEJM199005033221805] [PMID: 2271017]
[11]
Badghaish MMO, Qorban GNM, Albaqami AS, et al. Rheumatoid arthritis, pathophysiology and management. Egypt J Hosp Med 2018; 70(11): 1898-903.
[http://dx.doi.org/10.12816/0044839]
[12]
Arend WP. The pathophysiology and treatment of Rheumatoid arthritis. Arthritis Rheum 1997; 40(4): 595-7.
[http://dx.doi.org/10.1002/art.1780400402] [PMID: 9125239]
[13]
Gibofsky A. Overview of epidemiology, pathophysiology, and diagnosis of Rheumatoid arthritis. Am J Manag Care 2012; 18(13): S295-302. (Suppl.)
[PMID: 23327517]
[14]
Saxena A, Raychaudhuri SK, Raychaudhuri SP. Rheumatoid arthritis: Disease pathophysiology. inflammation, advancing age and nutrition. united states: academic press 2014.
[15]
Butola LK, Anjanker A, Vagga A, Kaple MN. Endogenous factor and pathophysiology of Rheumatoid arthritis: An autoimmune disease from decades. Int J Curr Res Rev 2020; 12(22): 34-40.
[http://dx.doi.org/10.31782/IJCRR.2020.122216]
[16]
Adami G, Saag KG. Osteoporosis pathophysiology, epidemiology, and screening in rheumatoid arthritis. Curr Rheumatol Rep 2019; 21(7): 34.
[http://dx.doi.org/10.1007/s11926-019-0836-7] [PMID: 31123839]
[17]
Gabriel SE. The epidemiology of rheumatoid arthritis. Rheum Dis Clin North Am 2001; 27(2): 269-81.
[http://dx.doi.org/10.1016/s0889-857x(05)70201-5]
[18]
Finckh A, Gilbert B, Hodkinson B, et al. Global epidemiology of rheumatoid arthritis. Nat Rev Rheumatol 2022; 18(10): 591-602.
[PMID: 36068354]
[19]
Myasoedova E, Davis JM, Crowson CS, Gabriel SE. Epidemiology of rheumatoid arthritis: Rheumatoid arthritis and mortality. Curr Rheumatol Rep 2010; 12(5): 379-85.
[http://dx.doi.org/10.1007/s11926-010-0117-y] [PMID: 20645137]
[20]
Gabriel SE, Crowson CS, O’Fallon M. The epidemiology of rheumatoid arthritis in Rochester, Minnesota, 1955-1985. Arthritis Rheum 1999; 42(3): 415-20.
[http://dx.doi.org/10.1002/1529-0131(199904)42:3<415:AID-ANR4>3.0.CO;2-Z] [PMID: 10088762]
[21]
Aho K, Kaipiainen-Seppänen O, Heliövaara M, Klaukka T. Epidemiology of rheumatoid arthritis in Finland. Semin Arthritis Rheum 1998; 27(5): 325-34.
[http://dx.doi.org/10.1016/S0049-0172(98)80053-x]
[22]
Widdifield J, Paterson JM, Bernatsky S, et al. The epidemiology of rheumatoid arthritis in Ontario, Canada. Arthritis Rheumatol 2014; 66(4): 786-93.
[http://dx.doi.org/10.1002/art.38306] [PMID: 24757131]
[23]
Silman AJ. Epidemiology of rheumatoid arthritis. Acta Pathol Microbiol Scand Suppl 1994; 102(7-12): 721-8.
[http://dx.doi.org/10.1111/j.1699-0463.1994.tb05226.x] [PMID: 7826600]
[24]
Okada Y, Wu D, Trynka G, et al. Genetics of Rheumatoid arthritis contributes to biology and drug discovery. Nature 2014; 506(7488): 376-81.
[http://dx.doi.org/10.1038/nature12873] [PMID: 24390342]
[25]
Raychaudhuri S. Recent advances in the genetics of Rheumatoid arthritis. Curr Opin Rheumatol 2010; 22(2): 109-18.
[http://dx.doi.org/10.1097/BOR.0b013e328336474d] [PMID: 20075733]
[26]
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis. An approach to understanding the molecular genetics of susceptibility to rheumatoid arthritis. Arthritis Rheum 1987; 30(11): 1205-13.
[http://dx.doi.org/10.1002/art.1780301102] [PMID: 2446635]
[27]
Viatte S, Plant D, Raychaudhuri S. Genetics and epigenetics of Rheumatoid arthritis. Nat Rev Rheumatol 2013; 9(3): 141-53.
[http://dx.doi.org/10.1038/nrrheum.2012.237] [PMID: 23381558]
[28]
Scally SW, Petersen J, Law SC, et al. A molecular basis for the association of the HLA-DRB1 locus, citrullination, and rheumatoid arthritis. J Exp Med 2013; 210(12): 2569-82.
[http://dx.doi.org/10.1084/jem.20131241] [PMID: 24190431]
[29]
Eyre S, Bowes J, Diogo D, et al. High-density genetic mapping identifies new susceptibility loci for Rheumatoid arthritis. Nat Genet 2012; 44(12): 1336-40.
[http://dx.doi.org/10.1038/ng.2462] [PMID: 23143596]
[30]
Källberg H, Ding B, Padyukov L, et al. Smoking is a major preventable risk factor for rheumatoid arthritis: estimations of risks after various exposures to cigarette smoke. Ann Rheum Dis 2011; 70(3): 508-11.
[http://dx.doi.org/10.1136/ard.2009.120899] [PMID: 21149499]
[31]
Plant D, Bowes J, Potter C, Hyrich KL, Morgan AW, Wilson AG. Genome-wide association study of genetic predictors of anti-TNF treatment response in rheumatoid arthritis. Ann Rheum Dis 2011; 70(6): 972-7.
[32]
Knevel R, Krabben A, Brouwer E, Landewe R, van der Heijde D, Huizinga TW. Genetics of rheumatoid arthritis contributes to the prediction of anti-TNF treatment response. Ann Rheum Dis 2014; 73(3): 463-5.
[33]
Aletaha D, Neogi T, Silman AJ, et al. Rheumatoid arthritis classification criteria: An American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum 2010; 62(9): 2569-81.
[http://dx.doi.org/10.1002/art.27584] [PMID: 20872595]
[34]
Nishimura K, Sugiyama D, Kogata Y. Diagnostic accuracy of anti-CCP antibody and RF for Rheumatoid arthritis. Ann Intern Med 2007; 146(11): 797-808.
[http://dx.doi.org/10.7326/0003-4819-146-11-200706050-00008] [PMID: 17548411]
[35]
Feldmann M, Maini RN. TNF defined as a therapeutic target for RA. J Clin Invest 2001; 107(3): 299-306.
[36]
Gregersen PK, Silver J, Winchester RJ. The shared epitope hypothesis in RA: A decade later. Arthritis Rheum 1996; 39(3): 340-53.
[37]
Raychaudhuri S. Recent advances in the genetics of RA. Curr Opin Rheumatol 2010; 22(2): 109-18.
[http://dx.doi.org/10.1097/BOR.0b013e328336474d] [PMID: 20075733]
[38]
Vang T, Congia M, Macis MD. PTPN22 polymorphism in RA. Nat Genet 2005; 37(12): 1317-9.
[http://dx.doi.org/10.1038/ng1673] [PMID: 16273109]
[39]
Remmers EF, Plenge RM, Lee AT. STAT4 and RA. N Engl J Med 2007; 357(10): 977-86.
[http://dx.doi.org/10.1056/NEJMoa073003] [PMID: 17804842]
[40]
Choy EH, Panayi GS. Cytokine pathways and joint inflammation in RA. N Engl J Med 2001; 344(12): 907-16.
[http://dx.doi.org/10.1056/NEJM200103223441207] [PMID: 11259725]
[41]
Klareskog L, Catrina AI, Paget S. Rheumatoid arthritis. Lancet 2009; 373(9664): 659-72.
[http://dx.doi.org/10.1016/S0140-6736(09)60008-8] [PMID: 19157532]
[42]
Haroon N, Aggarwal A, Lawrence A, Agarwal V, Misra R. Impact of Rheumatoid arthritis on quality of life. Mod Rheumatol 2007; 17(4): 290-5.
[http://dx.doi.org/10.3109/s10165-007-0604-9] [PMID: 17694261]
[43]
Matcham F, Scott IC, Rayner L, et al. The impact of Rheumatoid arthritis on quality-of-life assessed using the SF-36: A systematic review and meta-analysis. Semin Arthritis Rheum 2014; 44(2): 123-30.
[http://dx.doi.org/10.1016/j.semarthrit.2014.05.001] [PMID: 24973898]
[44]
Strand V, Khanna D. The impact of Rheumatoid arthritis and treatment on patients’ lives. Clin Exp Rheumatol 2010; 28(3): S32-40.
[PMID: 20576223]
[45]
Pollard L, Choy EH, Scott DL. The consequences of Rheumatoid arthritis: Quality of life measures in the individual patient. Clin Exp Rheumatol 2005; 23(5): S43-52.
[PMID: 16273784]
[46]
Martinec R, Pinjatela R, Balen D. Quality of life in patients with Rheumatoid arthritis–A preliminary study. Acta Clin Croat 2019; 58(1): 157-66.
[http://dx.doi.org/10.20471/acc.2019.58.01.20] [PMID: 31363338]
[47]
Rupp I, Boshuizen HC, Jacobi CE, Dinant HJ, van den Bos GAM. Impact of fatigue on health‐related quality of life in Rheumatoid arthritis. Arthritis Care Res 2004; 51(4): 578-85.
[http://dx.doi.org/10.1002/art.20539] [PMID: 15334430]
[48]
Shams S, Martinez JM, Dawson JRD, et al. The therapeutic landscape of Rheumatoid arthritis: Current state and future directions. Front Pharmacol 2021; 12: 680043.
[http://dx.doi.org/10.3389/fphar.2021.680043] [PMID: 34122106]
[49]
Ferrara F, Zovi A, Langella R, et al. Analysis of prescriptive monitoring regarding the current therapeutic landscape of Rheumatoid arthritis: The experience of an Italian local health authority. Expert Rev Pharmacoecon Outcomes Res 2025; 25(2): 227-33.
[http://dx.doi.org/10.1080/14737167.2024.2411431] [PMID: 39340396]
[50]
DeWitt EM, Brunner HI. The landscape of comparative effectiveness research in rheumatology. Nat Rev Rheumatol 2014; 10(1): 57-62.
[http://dx.doi.org/10.1038/nrrheum.2013.140] [PMID: 24061502]
[51]
Burmester GR, Pope JE. Novel treatment strategies in Rheumatoid arthritis. Lancet 2017; 389(10086): 2338-48.
[http://dx.doi.org/10.1016/S0140-6736(17)31491-5] [PMID: 28612748]
[52]
Gatto M, Zen M, Cruciani C, Iaccarino L, Doria A. Navigating the landscape of SLE treatment: An expert viewpoint on the rationality and limitations of early biologic intervention. Autoimmun Rev 2024; 23(10): 103612.
[http://dx.doi.org/10.1016/j.autrev.2024.103612] [PMID: 39218330]
[53]
Fonseca JE. SP0004 The therapeutic landscape in RA – bdmards, biosimilars and beyond. Ann Rheum Dis 2015; 74 (Supplement 22): 1-6.
[54]
He X, Yin J, Yu M, et al. Identification and validation of hub genes for predicting treatment targets and immune landscape in rheumatoid arthritis. BioMed Res Int 2022; 2022(1): 8023779.
[http://dx.doi.org/10.1155/2022/8023779] [PMID: 36317112]
[55]
Smolen JS, Aletaha D, Redlich K. The pathogenesis of Rheumatoid arthritis: New insights from old clinical data? Nat Rev Rheumatol 2012; 8(4): 235-43.
[http://dx.doi.org/10.1038/nrrheum.2012.23] [PMID: 22410633]
[56]
Ai R, Laragione T, Hammaker D, et al. Comprehensive epigenetic landscape of Rheumatoid arthritis fibroblast-like synoviocytes. Nat Commun 2018; 9(1): 1921.
[http://dx.doi.org/10.1038/s41467-018-04310-9] [PMID: 29765031]
[57]
van Vollenhoven R. Treat-to-target in Rheumatoid arthritis — Are we there yet? Nat Rev Rheumatol 2019; 15(3): 180-6.
[http://dx.doi.org/10.1038/s41584-019-0170-5] [PMID: 30700865]
[58]
Lau CS, Chia F, Harrison A, et al. APLAR Rheumatoid arthritis treatment recommendations. Int J Rheum Dis 2015; 18(7): 685-713.
[http://dx.doi.org/10.1111/1756-185X.12754] [PMID: 26334449]
[59]
Stoffer MA, Smolen JS, Woolf A, et al. Development of patient-centred standards of care for Rheumatoid arthritis in Europe: The eumusc.net project. Ann Rheum Dis 2014; 73(5): 902-5.
[http://dx.doi.org/10.1136/annrheumdis-2013-203743] [PMID: 23921994]
[60]
Sokka T, Hannonen P, Möttönen T. Conventional disease-modifying antirheumatic drugs in early arthritis. Rheum Dis Clin North Am 2005; 31(4): 729-44.
[http://dx.doi.org/10.1016/j.rdc.2005.07.007] [PMID: 16287594]
[61]
Han R, Ren HC, Zhou S, et al. Conventional disease-modifying anti-rheumatic drugs combined with Chinese Herbal Medicines for Rheumatoid arthritis: A systematic review and meta-analysis. J Tradit Complement Med 2022; 12(5): 437-46.
[http://dx.doi.org/10.1016/j.jtcme.2022.01.005] [PMID: 36081815]
[62]
Jurgens MS, Jacobs JWG, Bijlsma JWJ. The use of conventional disease-modifying anti-rheumatic drugs in established RA. Best Pract Res Clin Rheumatol 2011; 25(4): 523-33.
[http://dx.doi.org/10.1016/j.berh.2011.10.006] [PMID: 22137922]
[63]
Persson MSM, Sarmanova A, Doherty M, Zhang W. Conventional and biologic disease-modifying anti-rheumatic drugs for osteoarthritis: A meta-analysis of randomized controlled trials. Rheumatology 2018; 57(10): 1830-7.
[http://dx.doi.org/10.1093/rheumatology/key131] [PMID: 29917100]
[64]
Swierkot J, Szechiński J. Methotrexate in Rheumatoid arthritis. Pharmacol Rep 2006; 58(4): 473-92.
[PMID: 16963793]
[65]
Friedman B, Cronstein B. Methotrexate mechanism in treatment of Rheumatoid arthritis. Joint Bone Spine 2019; 86(3): 301-7.
[http://dx.doi.org/10.1016/j.jbspin.2018.07.004] [PMID: 30081197]
[66]
Kremer JM, Alarcón GS, Lightfoot RW, et al. Methotrexate for Rheumatoid arthritis. Arthritis Rheumatol 1994; 37(3): 316-28.
[67]
Lopez-Olivo MA, Siddhanamatha HR, Shea B, Tugwell P, Wells GA, Suarez-Almazor ME. Methotrexate for treating Rheumatoid arthritis. Cochrane Libr 2014; 2014(6): CD000957.
[http://dx.doi.org/10.1002/14651858.CD000957.pub2] [PMID: 24916606]
[68]
Weinblatt ME, Coblyn JS, Fox DA, et al. Efficacy of low-dose methotrexate in Rheumatoid arthritis. N Engl J Med 1985; 312(13): 818-22.
[http://dx.doi.org/10.1056/NEJM198503283121303] [PMID: 3883172]
[69]
Cronstein BN. Low-dose methotrexate: A mainstay in the treatment of Rheumatoid arthritis. Pharmacol Rev 2005; 57(2): 163-72.
[http://dx.doi.org/10.1124/pr.57.2.3] [PMID: 15914465]
[70]
Lipsky PE, van der Heijde DM, St Clair EW, et al. Infliximab and methotrexate in the treatment of Rheumatoid arthritis. N Engl J Med 2000; 343(22): 1594-602.
[http://dx.doi.org/10.1056/NEJM200011303432202] [PMID: 11096166]
[71]
Borchers AT, Keen CL, Cheema GS, Gershwin ME. The use of methotrexate in Rheumatoid arthritis. Semin Arthritis Rheum 2004; 34(1): 465-83.
[http://dx.doi.org/10.1016/j.semarthrit.2003.12.003] [PMID: 15305245]
[72]
Wang W, Zhou H, Liu L. Side effects of methotrexate therapy for Rheumatoid arthritis: A systematic review. Eur J Med Chem 2018; 158: 502-16.
[http://dx.doi.org/10.1016/j.ejmech.2018.09.027] [PMID: 30243154]
[73]
Plosker GL, Croom KF. Sulfasalazine. Drugs 2005; 65(13): 1825-49.
[http://dx.doi.org/10.2165/00003495-200565130-00008] [PMID: 16114981]
[74]
Michel F, Navellou JC, Ferraud D, Toussirot E, Wendling D. DRESS syndrome in a patient on sulfasalazine for Rheumatoid arthritis. Joint Bone Spine 2005; 72(1): 82-5.
[http://dx.doi.org/10.1016/j.jbspin.2004.06.002] [PMID: 15681256]
[75]
Suarez‐Almazor ME, Belseck E, Shea B, Tugwell P, Wells GA. Sulfasalazine for treating Rheumatoid arthritis. Cochrane Database Syst Rev 1998; 1998(2): CD000958.
[76]
Aletaha D, Stamm T, Kapral T, et al. Survival and effectiveness of leflunomide compared with methotrexate and sulfasalazine in Rheumatoid arthritis: A matched observational study. Ann Rheum Dis 2003; 62(10): 944-51.
[http://dx.doi.org/10.1136/ard.62.10.944] [PMID: 12972472]
[77]
Volin MV, Campbell PL, Connors MA, Woodruff DC, Koch AE. The effect of sulfasalazine on Rheumatoid arthritic synovial tissue chemokine production. Exp Mol Pathol 2002; 73(2): 84-92.
[http://dx.doi.org/10.1006/exmp.2002.2460] [PMID: 12231210]
[78]
Jansen G, van der Heijden J, Oerlemans R, et al. Sulfasalazine is a potent inhibitor of the reduced folate carrier: Implications for combination therapies with methotrexate in Rheumatoid arthritis. Arthritis Rheum 2004; 50(7): 2130-9.
[http://dx.doi.org/10.1002/art.20375] [PMID: 15248210]
[79]
Rempenault C, Combe B, Barnetche T, et al. Clinical and structural efficacy of hydroxychloroquine in Rheumatoid arthritis: A systematic review. Arthritis Care Res 2020; 72(1): 36-40.
[http://dx.doi.org/10.1002/acr.23826] [PMID: 30629341]
[80]
Wasko MCM, Hubert HB, Lingala VB, et al. Hydroxychloroquine and risk of diabetes in patients with Rheumatoid arthritis. JAMA 2007; 298(2): 187-93.
[http://dx.doi.org/10.1001/jama.298.2.187] [PMID: 17622600]
[81]
Rempenault C, Combe B, Barnetche T, et al. Metabolic and cardiovascular benefits of hydroxychloroquine in patients with Rheumatoid arthritis: A systematic review and meta-analysis. Ann Rheum Dis 2018; 77(1): 98-103.
[http://dx.doi.org/10.1136/annrheumdis-2017-211836] [PMID: 28970215]
[82]
Van Der Heijde D, Van Riel P, Gribnau FW, Nuver-Zwart IH, Van De Putte LB. Effects of hydroxychloroquine and sulphasalazine on progression of joint damage in Rheumatoid arthritis. Lancet 1989; 333(8646): 1036-8.
[http://dx.doi.org/10.1016/S0140-6736(89)92442-2] [PMID: 2565997]
[83]
A randomized trial of hydroxychloroquine in early Rheumatoid arthritis: The HERA study. Am J Med 1995; 98(2): 156-68.
[http://dx.doi.org/10.1016/S0002-9343(99)80399-4] [PMID: 7847432]
[84]
Laha A, Nasra S, Bhatia D, Kumar A. Advancements in Rheumatoid arthritis therapy: A journey from conventional therapy to precision medicine via nanoparticles targeting immune cells. Nanoscale 2024; 16(32): 14975-93.
[http://dx.doi.org/10.1039/D4NR02182G] [PMID: 39056352]
[85]
Akram M, Daniyal M, Sultana S, et al. Traditional and modern management strategies for Rheumatoid arthritis. Clin Chim Acta 2021; 512: 142-55.
[http://dx.doi.org/10.1016/j.cca.2020.11.003] [PMID: 33186593]
[86]
Schett G, Emery P, Tanaka Y, et al. Tapering biologic and conventional DMARD therapy in Rheumatoid arthritis: Current evidence and future directions. Ann Rheum Dis 2016; 75(8): 1428-37.
[http://dx.doi.org/10.1136/annrheumdis-2016-209201] [PMID: 27261493]
[87]
Sepehrifar MS, Karimifar M, Moussavi H, et al. The effects of conventional drugs in the treatment of Rheumatoid arthritis on the serum lipids. J Res Med Sci 2018; 23(1): 105.
[http://dx.doi.org/10.4103/jrms.JRMS_869_17] [PMID: 30693040]
[88]
Bingham SJ, Buch MH, Tennant A, Emery P. The impact of escalating conventional therapy in Rheumatoid arthritis patients referred for anti-tumour necrosis factor- therapy. Br J Rheumatol 2003; 43(3): 364-8.
[http://dx.doi.org/10.1093/rheumatology/keh057] [PMID: 14657509]
[89]
Bilsborough W, Keen H, Taylor A, O’Driscoll GJ, Arnolda L, Green DJ. Anti-tumour necrosis factor-alpha therapy over conventional therapy improves endothelial function in adults with Rheumatoid arthritis. Rheumatol Int 2006; 26(12): 1125-31.
[http://dx.doi.org/10.1007/s00296-006-0147-y] [PMID: 16799778]
[90]
Ma X, Xu S. TNF inhibitor therapy for Rheumatoid arthritis. Biomed Rep 2013; 1(2): 177-84.
[http://dx.doi.org/10.3892/br.2012.42] [PMID: 24648915]
[91]
Rubbert-Roth A, Finckh A. Treatment options in patients with Rheumatoid arthritis failing initial TNF inhibitor therapy: a critical review. Arthritis Res Ther 2009; 11 (Suppl. 1): S1.
[http://dx.doi.org/10.1186/ar2666] [PMID: 19368701]
[92]
Mewar D, Wilson AG. Treatment of Rheumatoid arthritis with tumour necrosis factor inhibitors. Br J Pharmacol 2011; 162(4): 785-91.
[http://dx.doi.org/10.1111/j.1476-5381.2010.01099.x] [PMID: 21039421]
[93]
Scott DL, Kingsley GH. Tumor necrosis factor inhibitors for Rheumatoid arthritis. N Engl J Med 2006; 355(7): 704-12.
[http://dx.doi.org/10.1056/NEJMct055183] [PMID: 16914706]
[94]
Segal B, Rhodus NL, Patel K. Tumor necrosis factor (TNF) inhibitor therapy for Rheumatoid arthritis. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 2008; 106(6): 778-87.
[http://dx.doi.org/10.1016/j.tripleo.2008.07.025] [PMID: 18930662]
[95]
Wollheim FA. TNF inhibition as therapy for Rheumatoid arthritis. Expert Opin Investig Drugs 2002; 11(7): 947-53.
[http://dx.doi.org/10.1517/13543784.11.7.947] [PMID: 12084005]
[96]
Leandro MJ, Edwards JCW, Cambridge G. Clinical outcome in 22 patients with Rheumatoid arthritis treated with B lymphocyte depletion. Ann Rheum Dis 2002; 61(10): 883-8.
[http://dx.doi.org/10.1136/ard.61.10.883] [PMID: 12228157]
[97]
Finckh A, Ciurea A, Brulhart L, et al. B cell depletion may be more effective than switching to an alternative anti–tumor necrosis factor agent in Rheumatoid arthritis patients with inadequate response to anti–tumor necrosis factor agents. Arthritis Rheum 2007; 56(5): 1417-23.
[http://dx.doi.org/10.1002/art.22520] [PMID: 17469098]
[98]
Calero I, Nieto JA, Sanz I. B cell therapies for Rheumatoid arthritis: Beyond B cell depletion. Rheum Dis Clin North Am 2010; 36(2): 325-43.
[http://dx.doi.org/10.1016/j.rdc.2010.02.003] [PMID: 20510237]
[99]
Edwards JCW, Cambridge G. B-cell targeting in Rheumatoid arthritis and other autoimmune diseases. Nat Rev Immunol 2006; 6(5): 394-403.
[http://dx.doi.org/10.1038/nri1838] [PMID: 16622478]
[100]
Mota P, Reddy V, Isenberg D. Improving B-cell depletion in systemic lupus erythematosus and Rheumatoid arthritis. Expert Rev Clin Immunol 2017; 13(7): 667-76.
[http://dx.doi.org/10.1080/1744666X.2017.1259068] [PMID: 27841031]
[101]
Teng YKO, Wheater G, Hogan VE, et al. Induction of long-term B-cell depletion in refractory Rheumatoid arthritis patients preferentially affects autoreactive more than protective humoral immunity. Arthritis Res Ther 2012; 14(2): R57.
[http://dx.doi.org/10.1186/ar3770] [PMID: 22409963]
[102]
Cambridge G, Leandro MJ, Edwards JCW, et al. Serologic changes following B lymphocyte depletion therapy for Rheumatoid arthritis. Arthritis Rheum 2003; 48(8): 2146-54.
[http://dx.doi.org/10.1002/art.11181] [PMID: 12905467]
[103]
Popa C, Leandro MJ, Cambridge G, Edwards JCW. Repeated B lymphocyte depletion with rituximab in Rheumatoid arthritis over 7 yrs. Rheumatology 2006; 46(4): 626-30.
[http://dx.doi.org/10.1093/rheumatology/kel393] [PMID: 17189244]
[104]
Malemud CJ. The role of the JAK/STAT signal pathway in Rheumatoid arthritis. Ther Adv Musculoskelet Dis 2018; 10(5-6): 117-27.
[http://dx.doi.org/10.1177/1759720X18776224] [PMID: 29942363]
[105]
Simon LS, Taylor PC, Choy EH, et al. The Jak/STAT pathway: A focus on pain in Rheumatoid arthritis. Semin Arthritis Rheum 2021; 51(1): 278-84.
[http://dx.doi.org/10.1016/j.semarthrit.2020.10.008] [PMID: 33412435]
[106]
Ciobanu DA, Poenariu IS, Crînguș LI, et al. JAK/STAT pathway in pathology of Rheumatoid arthritis (Review). Exp Ther Med 2020; 20(4): 3498-503.
[http://dx.doi.org/10.3892/etm.2020.8982] [PMID: 32905201]
[107]
Isomäki P, Junttila I, Vidqvist KL, Korpela M, Silvennoinen O. The activity of JAK-STAT pathways in Rheumatoid arthritis: constitutive activation of STAT3 correlates with interleukin 6 levels. Rheumatology 2015; 54(6): 1103-13.
[http://dx.doi.org/10.1093/rheumatology/keu430] [PMID: 25406356]
[108]
Hu L, Liu R, Zhang L. Advance in bone destruction participated by JAK/STAT in Rheumatoid arthritis and therapeutic effect of JAK/STAT inhibitors. Int Immunopharmacol 2022; 111: 109095.
[http://dx.doi.org/10.1016/j.intimp.2022.109095] [PMID: 35926270]
[109]
Walker JG, Ahern MJ, Coleman M, et al. Changes in synovial tissue Jak-STAT expression in Rheumatoid arthritis in response to successful DMARD treatment. Ann Rheum Dis 2006; 65(12): 1558-64.
[http://dx.doi.org/10.1136/ard.2005.050385] [PMID: 16760256]
[110]
Baldini C, Moriconi FR, Galimberti S, Libby P, De Caterina R. The JAK–STAT pathway: An emerging target for cardiovascular disease in Rheumatoid arthritis and myeloproliferative neoplasms. Eur Heart J 2021; 42(42): 4389-400.
[http://dx.doi.org/10.1093/eurheartj/ehab447] [PMID: 34343257]
[111]
Palmroth M, Kuuliala K, Peltomaa R, et al. Tofacitinib suppresses several JAK-STAT pathways in Rheumatoid arthritis in vivo and baseline signaling profile associates with treatment response. Front Immunol 2021; 12: 738481.
[http://dx.doi.org/10.3389/fimmu.2021.738481] [PMID: 34630419]
[112]
McGarry T, Orr C, Wade S, et al. JAK/STAT blockade alters synovial bioenergetics, mitochondrial function, and proinflammatory mediators in Rheumatoid arthritis. Arthritis Rheumatol 2018; 70(12): 1959-70.
[http://dx.doi.org/10.1002/art.40569] [PMID: 29790294]
[113]
Malemud CJ, Miller AH. Pro-inflammatory cytokine-induced SAPK/MAPK and JAK/STAT in Rheumatoid arthritis and the new anti-depression drugs. Expert Opin Ther Targets 2008; 12(2): 171-83.
[http://dx.doi.org/10.1517/14728222.12.2.171] [PMID: 18208366]
[114]
Kalden JR. Emerging therapies for Rheumatoid arthritis. Rheumatol Ther 2016; 3(1): 31-42.
[http://dx.doi.org/10.1007/s40744-016-0032-4] [PMID: 27747522]
[115]
Zhou Q, Haupt S, Kreuzer JT. Decreased expression of miR-146a and miR-155 contributes to an abnormal Treg phenotype in patients with Rheumatoid arthritis. Ann Rheum Dis 2015; 74(6): 1265-74.
[http://dx.doi.org/10.1136/annrheumdis-2013-204377] [PMID: 24562503]
[116]
Suntharalingam G, Perry MR, Ward S. Cytokine storm in a phase 1 trial of the anti-CD28 monoclonal antibody TGN1412. N Engl J Med 2006; 355(10): 1018-28.
[http://dx.doi.org/10.1056/NEJMoa063842] [PMID: 16908486]
[117]
Hsu YH, Li HH, Hsieh MY. Interleukin-20 promotes proliferation and osteoclastogenesis in Rheumatoid arthritis. Arthritis Rheum 2006; 54(9): 2725-35.
[PMID: 16947773]
[118]
Genovese MC, Fleischmann R, Combe B. Safety and efficacy of upadacitinib in patients with active Rheumatoid arthritis refractory to biologic DMARDs (SELECT-BEYOND): A double-blind, randomized controlled phase 3 trial. Lancet 2018; 391(10139): 2513-24.
[http://dx.doi.org/10.1016/S0140-6736(18)31116-4] [PMID: 29908670]
[119]
Chondrogianni N, Stratford FLL, Trougakos IP, Friguet B, Rivett AJ, Gonos ES. Central role of the proteasome in senescence and survival of human fibroblasts: Induction of a senescence-like phenotype upon its inhibition and resistance to stress upon its activation. J Biol Chem 2003; 278(30): 28026-37.
[http://dx.doi.org/10.1074/jbc.M301048200] [PMID: 12736271]
[120]
Ritchlin CT, Rahman P, Kavanaugh A. Efficacy and safety of the anti–interleukin-17A monoclonal antibody secukinumab in patients with psoriatic arthritis: A randomized, double-blind, placebo-controlled, phase II study. Arthritis Rheumatol 2014; 66(2): 349-59.
[121]
Senolt L. Emerging therapies in Rheumatoid arthritis: Focus on monoclonal antibodies. F1000 Res 2019; 8: 1549.
[http://dx.doi.org/10.12688/f1000research.18688.1] [PMID: 31508202]
[122]
Doan T, Massarotti E. Rheumatoid arthritis: An overview of new and emerging therapies. J Clin Pharmacol 2005; 45(7): 751-62.
[http://dx.doi.org/10.1177/0091270005277938] [PMID: 15951465]
[123]
Khokhar M, Dey S, Tomo S, Jaremko M, Emwas AH, Pandey RK. Unveiling novel drug targets and emerging therapies for Rheumatoid arthritis: A comprehensive review. ACS Pharmacol Transl Sci 2024; 7(6): 1664-93.
[http://dx.doi.org/10.1021/acsptsci.4c00067] [PMID: 38898941]
[124]
Blumberg SN, Fox DA. Rheumatoid arthritis: Guidelines for emerging therapies. Am J Manag Care 2001; 7(6): 617-26.
[PMID: 11439735]
[125]
Feely M. New and emerging therapies for the treatment of Rheumatoid arthritis. Open Access Rheumatol 2010; 2: 35-43.
[http://dx.doi.org/10.2147/OARRR.S6868] [PMID: 27789996]
[126]
Clements JN. Treatment of Rheumatoid arthritis: A review of recommendations and emerging therapy. Formulary 2011; 46(12): 532.
[127]
Ben Mrid R, Bouchmaa N, Ainani H, El Fatimy R, Malka G, Mazini L. Anti-Rheumatoid drugs advancements: New insights into the molecular treatment of Rheumatoid arthritis. Biomed Pharmacother 2022; 151: 113126.
[http://dx.doi.org/10.1016/j.biopha.2022.113126] [PMID: 35643074]
[128]
Breedveld FC, Combe B. Understanding emerging treatment paradigms in Rheumatoid arthritis. Arthritis Res Ther 2011; 13(S1): S3.
[http://dx.doi.org/10.1186/1478-6354-13-S1-S3] [PMID: 21624182]
[129]
Ringold S, Angeles-Han ST, Beukelman T, et al. 2019 American College of Rheumatology/Arthritis Foundation guideline for the treatment of juvenile idiopathic arthritis: Therapeutic approaches for non-systemic polyarthritis, sacroiliitis, and enthesitis. Arthritis Care Res 2019; 71(6): 717-34.
[http://dx.doi.org/10.1002/acr.23870] [PMID: 31021516]
[130]
Ravelli A, Consolaro A, Horneff G, et al. Treating juvenile idiopathic arthritis to target: Recommendations of an international task force. Ann Rheum Dis 2018; 77(6): 819-28.
[http://dx.doi.org/10.1136/annrheumdis-2018-213030] [PMID: 29643108]

Rights & Permissions Print Cite
Article Metrics
Pdf icon 17
Html icon 1
Find your institution